Open an account

Solid Biosciences

SLDB · NASDAQ

$6.40+$0.48 (+8.11%)TodayMarket closed ·
Prev close $5.92

About SLDB

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Employees
121
Headquarters
Charlestown, Massachusetts
Listed
Jan 26, 2018
Sector
Health Care
Industry
Biotechnology
Website
solidbio.com

SLDB key statistics

Market cap
686.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.43M
Volume
1.47M
Open price
$5.93
High today
$6.52
Low today
$5.86
52 Week high
$11.45
52 Week low
$3.79

Solid Biosciences (SLDB) at a glance

Solid Biosciences (SLDB) last traded at $6.40, with a market cap of 686.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.86 and $6.52. The current price is 9.2% above the day's low and 1.8% below its high.

Volume so far is 1.47M shares, in line with the average of 1.43M shares a day.

Over the past year Solid Biosciences has ranged from $3.79 to $11.45, and now sits 34% of the way up that range.

Solid Biosciences met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.38 per share against an estimate of -$0.4776.

The average analyst price target is $19.30, 201.6% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 13 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 16 analystsAvg $19.30
Low
$14.14
Now
$6.40
High
$27.30

SLDB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 19.4% on average.

  1. Q3 FY24: reported -$0.79 per share against an estimate of -$0.6809
  2. Q4 FY24: reported -$1.00 per share against an estimate of -$0.8223
  3. Q1 FY25: reported -$0.59 per share against an estimate of -$0.5669
  4. Q2 FY25: reported -$0.42 per share against an estimate of -$0.5142
  5. Q3 FY25: reported -$0.48 per share against an estimate of -$0.4475
  6. Q4 FY25: reported -$0.53 per share against an estimate of -$0.5292
  7. Q1 FY26: reported -$0.52 per share against an estimate of -$0.4422
  8. Q2 FY26: reported -$0.38 per share against an estimate of -$0.4776

SLDB news

  • Press releaseGlobe Newswire

    Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Solid Biosciences to Participate at Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

  • Vandana Singh

    What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releasePRNewswire

    Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

  • Press releaseGlobe Newswire

    Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Similar companies

Companies in the same industry as Solid Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.